{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:42:06Z","timestamp":1791610926534,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.pan.2020.10.029","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T19:32:03Z","timestamp":1602358323000},"page":"192-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Early dose reduction\/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1"],"prefix":"10.1016","volume":"21","author":[{"given":"Li-Tzong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beloo","family":"Mirakhur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-5814","authenticated-orcid":false,"given":"Bruce","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-4778","authenticated-orcid":false,"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2020.10.029_bib1","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/annonc\/mdu138","article-title":"European cancer mortality predictions for the year 2014","volume":"25","author":"Malvezzi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib2","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pan.2020.10.029_bib3","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib4","series-title":"SEER cancer statistics review","author":"Howlader","year":"1975"},{"key":"10.1016\/j.pan.2020.10.029_bib5","series-title":"NCCN guidelines version 1.2019 pancreatic adenocarcinoma","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"10.1016\/j.pan.2020.10.029_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ags3.12176","article-title":"Immunotherapy for pancreatic cancer: barriers and breakthroughs","volume":"2","author":"Torphy","year":"2018","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.pan.2020.10.029_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12876-017-0709-3","article-title":"Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient","volume":"17","author":"Berger","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.pan.2020.10.029_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.21037\/jgo.2016.01.03","article-title":"Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial","volume":"7","author":"Scheithauer","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2020.10.029_bib11","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2020.10.029_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pan.2020.10.029_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.pan.2020.10.029_bib14","doi-asserted-by":"crossref","first-page":"iv157","DOI":"10.1093\/annonc\/mdx244","article-title":"Appendix 6: cancer of the pancreas: MCBS eUpdate published online 20 June 2017","volume":"28","author":"ESMO","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.9636","article-title":"Metastatic pancreatic cancer: ASCO clinical practice guideline update","author":"Sohal","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2011.10.003","article-title":"Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer","volume":"124","author":"Nagel","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib17","series-title":"Common terminology criteria for adverse events (CTCAE) v4.0","author":"Cancer Therapy Evaluation Program","year":"2010"},{"key":"10.1016\/j.pan.2020.10.029_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw582.023","article-title":"Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) \u00b1 5-fluorouracil and leucovorin (5-FU\/LV) vs 5-FU\/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy","volume":"27","author":"Hubner","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pan.2020.10.029_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2018.09.010","article-title":"Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: expanded analysis of a global phase 3 trial","volume":"105","author":"Chen","year":"2018","journal-title":"Eur J Canc"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390320307808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390320307808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:12:41Z","timestamp":1761408761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390320307808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1424390320307808"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2020.10.029","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early dose reduction\/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2020.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}